After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
The American Gastroenterological Association (AGA) released a set of guidelines that outlines the use of biomarkers to treat and monitor ulcerative colitis in patients.
The American College of Gastroenterology (ACG) provides new updates for clinicians and patients with recommendations for the diagnosis and management of celiac disease.
Researchers examined the impact that time-to-initiation of biologic treatment had on the risk of adverse outcomes among individuals with Crohn disease.
The authors of a first-of-its-kind systematic review examined if using probiotics concomitantly with antibiotics regimens could impact antibiotic-induced changes to the gut microbiome.
Benign anorectal disorders are often distressing, debilitating, and add significantly to the health care burden. This article summarizes a presentation on benign anorectal disorders by Damanpreet K. Grewal,...
A randomized Phase 3 U-ENDURE maintenance study compared the safety and efficacy of upadacitinib with placebo for the treatment of patients with moderate-to-severe Crohn disease.
